Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

About

Brief Summary

This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer. Prostate cancer is the most diagnosed cancer in men and there are many treatments available, including surgery and radiation therapy. Although surgery and radiation therapy improve survival urinary and sexual function can be significantly affected and can be long lasting. HDR-BT, a type of focal radiation therapy also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving HDR-BT may be effective in providing local control while reducing side effects in patients with prostate cancer.

Primary Purpose

Treatment

Study Type

Interventional

Phase

Phase 2

Eligibility

Gender

Male

Healthy Volunteers

No

Minimum Age

40 Years

Maximum Age

N/A

Inclusion Criteria:

Histologically confirmed diagnosis of prostate adenocarcinoma within 90 days prior to registration via systematic biopsy
Multiparametric MRI (mp-MRI) confirmed lesion(s)
No distant or locally advanced disease on standard staging exams as indicated
- Bone scan and abdominopelvic computed tomography (CT)/MRI OR
- PSMA PET
Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status 0/1 within 60 days prior to enrollment
Age ≥ 40

Exclusion Criteria:

Radiographic nodal or distant metastatic disease
Lesion(s) comprising > 40% of total prostate volume
Prior radiotherapy to the pelvis
Gleason score > 6 disease outside intended gross target volume (GTV)/target region(s)

Not a fit? Find another study